FAS Wealth Partners Inc. Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

FAS Wealth Partners Inc. increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,286 shares of the company's stock after buying an additional 1,548 shares during the period. FAS Wealth Partners Inc.'s holdings in Johnson & Johnson were worth $6,681,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. WealthTrak Capital Management LLC bought a new position in Johnson & Johnson during the fourth quarter valued at about $26,000. Mountain Hill Investment Partners Corp. bought a new position in Johnson & Johnson during the fourth quarter valued at about $29,000. Conquis Financial LLC bought a new position in Johnson & Johnson during the fourth quarter valued at about $33,000. Bernard Wealth Management Corp. bought a new position in Johnson & Johnson during the fourth quarter valued at about $36,000. Finally, Highline Wealth Partners LLC grew its position in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

JNJ traded up $2.17 during midday trading on Tuesday, hitting $166.53. 3,265,074 shares of the company traded hands, compared to its average volume of 8,123,232. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $400.69 billion, a PE ratio of 17.78, a price-to-earnings-growth ratio of 2.08 and a beta of 0.41. The company's 50-day moving average is $154.29 and its 200 day moving average is $155.12. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The business's quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.82 EPS. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.12%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Raymond James Financial dropped their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price objective for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday. Finally, Bank of America lifted their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. Eleven research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus price target of $172.87.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.